Bullfrog AI (BFRG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Oct, 2026Executive summary
Virtual annual meeting scheduled for September 20, 2024; ballot covers four director elections and ratification of M & K CPAs, PLLC for FY2024. The Board recommended FOR both proposals.
Record date was July 29, 2024, with 7,850,550 common shares outstanding; each share carries one vote.
Voting matters and shareholder proposals
Four incumbent nominees stand for election until the next annual meeting; the four nominees receiving the most FOR votes will be elected, and the Board unanimously recommended FOR each.
Auditor ratification requires a majority of votes cast; abstentions and broker non-votes have no effect on either ballot item.
Stockholder proposals for inclusion in next year's proxy materials are due April 30, 2025; other proposals require notice by May 31, 2025.
Board of directors and corporate governance
Board nominees are Vininder Singh, R. Donald Elsey, William Enright and Jason D. Hanson; Elsey, Enright and Hanson were determined independent under Nasdaq rules.
Singh serves as both CEO and Board Chair; the Board considers the combined roles beneficial to operations and strategic oversight.
Audit, Compensation, and Nominating and Corporate Governance Committees each comprise the three independent directors; the Audit Committee met four times in 2023, while the other two committees did not meet.
The Board is developing a diversity policy and committed to seeking qualified women and minority and LGBTQ+ candidates; its August 2024 matrix listed one African American or Black director and three White directors.
Latest events from Bullfrog AI
- AI platform targets drug discovery economics, backed by a pharma deal and expanding pipeline.BFRG
LD Micro 20th Annual Main Event Conference - A warrant-resale registration amid early-stage drug development and ongoing funding needs.BFRG
Registration filing - Resale registration could yield up to $3.26M, contingent on cash warrant exercises.BFRG
Registration filing - Four proposals seek a $10M equity facility, reverse-split authority and expanded equity awards.BFRG
Proxy filing - A $100 million shelf backs an early-stage AI drug strategy facing financing and clinical risks.BFRG
Registration filing - Four directors face election as shareholders consider auditor ratification for FY2025.BFRG
Proxy filing - Votes cover financing dilution, a discretionary reverse split and a 750,000-share Plan increase.BFRG
Proxy filing - Amendment updates Item 16 and auditor consent; the continuous-offering framework remains.BFRG
Registration filing - A conditional $10 million equity facility brings potential liquidity and substantial dilution risk.BFRG
Registration filing